Afya To Buy Back Up To 4 Mln Of Class A Common Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 14 2025
0mins
Should l Buy AFYA?
Source: NASDAQ.COM
Share Repurchase Announcement: Afya Limited plans to repurchase up to 4 million of its Class A common shares from August 15, 2025, until December 31, 2026, depending on market conditions.
Purpose of Repurchase: The shares will be used for the company's stock option program, future business combinations, and general corporate purposes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AFYA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AFYA
Wall Street analysts forecast AFYA stock price to rise
5 Analyst Rating
1 Buy
4 Hold
0 Sell
Hold
Current: 14.490
Low
16.00
Averages
18.90
High
22.00
Current: 14.490
Low
16.00
Averages
18.90
High
22.00
About AFYA
Afya Ltd is a Brazil-based company engaged in the education sector. The Company is mainly focused on operating medical schools, offering health sciences courses, which comprise medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition and biomedicine. In addition, the Firm provides degree programs and courses in other subjects and disciplines, including undergraduate and post graduate courses in business administration, accounting, law, civil engineering, industrial engineering and pedagogy. The Company's methodological approach combines integrated content, interactive learning, and an adaptive experience for learners. Through its educational content and technology-enabled activities, the Company focuses on personalized learning that mirrors one-on-one tutoring. The Company's undergraduate and graduate campuses are spread across Brazil, as well as its digital medical platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Afya Secures Authorization for 63 Additional Medical Seats
- Seat Increase: Brazil's Ministry of Education has authorized Afya to add 63 medical seats at its Abaetetuba campus, bringing the total to 113 seats, thereby reinforcing its leadership in the Brazilian medical education sector.
- Campus Integration: The non-operational status of Afya Cametá allows for resource consolidation, enabling the Abaetetuba campus to expand its capacity, which optimizes educational resource allocation and enhances overall operational efficiency.
- Market Leadership: This expansion raises Afya's total approved medical seats to 3,766 across its portfolio, highlighting its strong influence and market share in the Brazilian medical education landscape.
- Commitment to Education: Afya's expansion plan not only enhances the quality of medical education but also strengthens its ability to provide comprehensive support to students and physicians, driving overall improvements in healthcare services.
See More
Afya Secures Approval for 63 Additional Medical Seats
- Seat Increase: The Brazilian Ministry of Education has authorized Afya to add 63 medical seats at its Abaetetuba campus, bringing the total to 113, further solidifying its leadership in Brazil's medical education sector.
- Strategic Integration: The non-operational status of Afya Cametá allows for resource optimization, enabling the expansion at Abaetetuba and enhancing overall educational quality.
- Market Leadership: With this expansion, Afya now boasts a total of 3,766 approved medical seats across its portfolio, showcasing its strong influence and growth potential in the Brazilian market.
- Commitment to Education: Afya is dedicated to enhancing the career development of students and physicians through a comprehensive medical education ecosystem, further promoting the delivery of high-quality healthcare services.
See More
Barclays Cuts BJ's Wholesale Price Target to $90
- Price Target Downgrade: Barclays has cut BJ's Wholesale Club's price target from $115 to $90, with analyst Seth Sigman downgrading the stock from Equal-Weight to Underweight, indicating a cautious outlook on the company's future performance.
- Market Reaction: BJ's Wholesale shares closed at $90.88 on Tuesday, nearing the new target price, which reflects the market's sensitivity to analyst rating changes and may impact investor confidence.
- Other Rating Changes: Mizuho slashed OneStream's price target from $25 to $24, downgrading the rating from Outperform to Neutral, suggesting a weakened expectation for the company's future growth.
- Industry Trends: JP Morgan lowered Afya's price target from $24.5 to $22, downgrading the stock from Overweight to Neutral, reflecting concerns about the overall outlook for the education technology sector, which may affect investor sentiment in this field.
See More
Afya Board Member Maria Tereza Azevedo Resigns, Impacting Decision-Making Diversity
- Board Changes: Afya announced that board member Maria Tereza Azevedo will resign effective December 31, 2025, which may impact the diversity and stability of the company's decision-making processes.
- Board Structure: The current board consists of two co-chairmen and several independent directors, ensuring a diverse range of skills and experiences that enhance Afya's decision-making quality.
- Company Background: Afya is a leading medical education group in Brazil, providing a comprehensive ecosystem from medical education to practice solutions, dedicated to supporting the career development of students and physicians.
- Future Outlook: Despite the board member change, Afya will continue to focus on its mission to enhance physicians' careers through high-quality education and healthcare services.
See More
Afya Limited Board Member Maria Tereza Azevedo Resigns, Effective December 31, 2025
- Board Change: Afya Limited announced that board member Maria Tereza Azevedo will resign effective December 31, 2025, which, while not immediately impacting operations, may have potential implications for future decision-making.
- Diversity Composition: The Afya board consists of two co-chairmen and several independent members, ensuring a diverse skill set and experience in the medical education sector, which enhances decision-making quality.
- Company Background: As Brazil's leading medical education group, Afya provides a comprehensive ecosystem from medical students to physicians, focused on improving healthcare service quality and supporting doctors throughout their careers.
- Future Outlook: Although Maria Tereza's resignation will not have an immediate effect on the company's strategy, the board's diversity and expertise will remain critical factors for Afya's future growth.
See More
Afya (AFYA) Exceeds Earnings Expectations in Q3
Earnings Performance: Afya (AFYA) reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.32, marking an 18.75% earnings surprise. The company has surpassed consensus EPS estimates three times in the last four quarters.
Revenue Insights: The company generated revenues of $170.44 million for the quarter, slightly missing the consensus estimate by 0.16%, but showing growth from $151.71 million a year ago. Afya has topped revenue estimates twice in the last four quarters.
Stock Outlook: Afya shares have declined by 9.1% year-to-date, underperforming the S&P 500's 16.4% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Schools industry, to which Afya belongs, is ranked in the bottom 32% of Zacks industries, suggesting potential challenges ahead. Investors are advised to monitor earnings estimate revisions and industry outlooks for future stock performance.
See More
Afya Secures Authorization for 63 Additional Medical Seats
- Seat Increase: Brazil's Ministry of Education has authorized Afya to add 63 medical seats at its Abaetetuba campus, bringing the total to 113 seats, thereby reinforcing its leadership in the Brazilian medical education sector.
- Campus Integration: The non-operational status of Afya Cametá allows for resource consolidation, enabling the Abaetetuba campus to expand its capacity, which optimizes educational resource allocation and enhances overall operational efficiency.
- Market Leadership: This expansion raises Afya's total approved medical seats to 3,766 across its portfolio, highlighting its strong influence and market share in the Brazilian medical education landscape.
- Commitment to Education: Afya's expansion plan not only enhances the quality of medical education but also strengthens its ability to provide comprehensive support to students and physicians, driving overall improvements in healthcare services.
See More
Afya Secures Approval for 63 Additional Medical Seats
- Seat Increase: The Brazilian Ministry of Education has authorized Afya to add 63 medical seats at its Abaetetuba campus, bringing the total to 113, further solidifying its leadership in Brazil's medical education sector.
- Strategic Integration: The non-operational status of Afya Cametá allows for resource optimization, enabling the expansion at Abaetetuba and enhancing overall educational quality.
- Market Leadership: With this expansion, Afya now boasts a total of 3,766 approved medical seats across its portfolio, showcasing its strong influence and growth potential in the Brazilian market.
- Commitment to Education: Afya is dedicated to enhancing the career development of students and physicians through a comprehensive medical education ecosystem, further promoting the delivery of high-quality healthcare services.
See More
Barclays Cuts BJ's Wholesale Price Target to $90
- Price Target Downgrade: Barclays has cut BJ's Wholesale Club's price target from $115 to $90, with analyst Seth Sigman downgrading the stock from Equal-Weight to Underweight, indicating a cautious outlook on the company's future performance.
- Market Reaction: BJ's Wholesale shares closed at $90.88 on Tuesday, nearing the new target price, which reflects the market's sensitivity to analyst rating changes and may impact investor confidence.
- Other Rating Changes: Mizuho slashed OneStream's price target from $25 to $24, downgrading the rating from Outperform to Neutral, suggesting a weakened expectation for the company's future growth.
- Industry Trends: JP Morgan lowered Afya's price target from $24.5 to $22, downgrading the stock from Overweight to Neutral, reflecting concerns about the overall outlook for the education technology sector, which may affect investor sentiment in this field.
See More
Afya Board Member Maria Tereza Azevedo Resigns, Impacting Decision-Making Diversity
- Board Changes: Afya announced that board member Maria Tereza Azevedo will resign effective December 31, 2025, which may impact the diversity and stability of the company's decision-making processes.
- Board Structure: The current board consists of two co-chairmen and several independent directors, ensuring a diverse range of skills and experiences that enhance Afya's decision-making quality.
- Company Background: Afya is a leading medical education group in Brazil, providing a comprehensive ecosystem from medical education to practice solutions, dedicated to supporting the career development of students and physicians.
- Future Outlook: Despite the board member change, Afya will continue to focus on its mission to enhance physicians' careers through high-quality education and healthcare services.
See More
Afya Limited Board Member Maria Tereza Azevedo Resigns, Effective December 31, 2025
- Board Change: Afya Limited announced that board member Maria Tereza Azevedo will resign effective December 31, 2025, which, while not immediately impacting operations, may have potential implications for future decision-making.
- Diversity Composition: The Afya board consists of two co-chairmen and several independent members, ensuring a diverse skill set and experience in the medical education sector, which enhances decision-making quality.
- Company Background: As Brazil's leading medical education group, Afya provides a comprehensive ecosystem from medical students to physicians, focused on improving healthcare service quality and supporting doctors throughout their careers.
- Future Outlook: Although Maria Tereza's resignation will not have an immediate effect on the company's strategy, the board's diversity and expertise will remain critical factors for Afya's future growth.
See More
Afya (AFYA) Exceeds Earnings Expectations in Q3
Earnings Performance: Afya (AFYA) reported quarterly earnings of $0.38 per share, exceeding the Zacks Consensus Estimate of $0.32, marking an 18.75% earnings surprise. The company has surpassed consensus EPS estimates three times in the last four quarters.
Revenue Insights: The company generated revenues of $170.44 million for the quarter, slightly missing the consensus estimate by 0.16%, but showing growth from $151.71 million a year ago. Afya has topped revenue estimates twice in the last four quarters.
Stock Outlook: Afya shares have declined by 9.1% year-to-date, underperforming the S&P 500's 16.4% gain. The stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Schools industry, to which Afya belongs, is ranked in the bottom 32% of Zacks industries, suggesting potential challenges ahead. Investors are advised to monitor earnings estimate revisions and industry outlooks for future stock performance.
See More
